Evaluating only Ampio Pharmaceuticals’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market timing.
Key Events Timeline
FOUNDING
MILESTONE
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Ampio developed Ampion, an anti-inflammatory derived from human serum albumin, for knee osteoarthritis. Years of trials failed to produce the clean efficacy data needed for FDA approval. A 2022 FDA advisory committee did not support approval. The company laid off all staff and wound down operations in late 2022 and 2023.
Lesson
“Orthopedic biotech programs need superiority over existing treatments, not just non-inferiority — the bar keeps rising as generics proliferate.”